Climb Bio reports strong B-cell depletion with budoprutug, advancing trials in autoimmune diseases with data expected in 2026

Climb Bio announced positive topline data showing robust B-cell depletion from its budoprutug subcutaneous formulation in healthy volunteers, supporting continued development. Budoprutug, an anti-CD19 monoclonal antibody, is being tested in clinical trials for primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE), with initial data expected throughout 2026. The drug has received Fast Track Designation for pMN and is being developed in both intravenous and subcutaneous forms to maximize patient access. Climb Bio highlights budoprutug's potential to provide durable disease control by targeting a broad range of B cells, including those not addressed by current therapies.